Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogenactivated protein kinase kinase kinase 1 (MEKK-1) expression

Molecular Cancer Therapeutics

Volumn 1, Issue 10, 2002, Pages 821-829

  Hershberger, Pamela A ^a   McGuire, Terence F ^a   Yu, Wei Dong ^a   Zuhowski, Eleanor G ^a   Schellens, Jan H M ^c   Egorin, Merrill J ^a,b   Trump, Donald L ^a,b   Johnson, Candace S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; CISPLATIN; COLORING AGENT; MAP3K1 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PROTEIN SERINE THREONINE KINASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL; APOPTOSIS; ARTICLE; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; DNA ADDUCT; DOSE RESPONSE; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CALCITRIOL; CELL SURVIVAL; CISPLATIN; COLORING AGENTS; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; MAP KINASE KINASE KINASE 1; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0036689119     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. 3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J. Steroid Biochem., 24: 373-376, 1986.
2. Colston, K. W., Chander, S. K., Mackay, A. G., and Coombes, R. C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44: 693-702, 1992.
3. 3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res., 1: 997-1003, 1995.
4. 3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132: 1952-1960, 1993.
5. 3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res., 60: 2304-2312, 2000.
6. 3 analog in a squamous cell carcinoma model system. Mol. Cell. Differ., 3: 31-50, 1995.
7. Light, B. W., Yu, W-D., McElwain, M. C., Russell, D. M., Trump, D. L., and Johnson, C. S. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res., 57: 3759-3764, 1997. (Pubitemid 27381220)
8. 3) inhibits the growth of squamous cell carcinoma and down-modulates p21Waf1/Cip1 in vitro and in vivo. Cancer Res., 59: 2644-2649, 1999.
9. 3-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J. Biol. Chem., 276: 26365-26373, 2001.
10. 3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin. Cancer Res., 5: 695-703, 1999.
11. 3 and platinum drugs on the growth of MCF-7 cells. Cancer Res., 51: 2848-2853, 1991.
12. Hershberger, P. A., Yu, W-D., Modzelewski, R. A., Rueger, R. M., Johnson, C. S., and Trump, D. L. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin. Cancer Res., 7: 1043-1051, 2001. (Pubitemid 32708744)
13. 3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res., 60: 2040-2048, 2000.
14. 3 analogs and paclitaxel on growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res. Treat., 53: 113-120, 1999.
15. 3 analog, ILX-23-7553, enhances the response to Adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother. Pharmacol., 47: 429-436, 2001.
16. Chu, G. Cellular responses to cisplatin. J. Biol. Chem., 269: 787-790, 1994.
17. Dasika, G. K., Lin, S-C. J., Zhao, S., Sung, P., Tomkinson, A., and Lee, E. Y-H. P. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene, 18: 7883- 7899, 1999.
18. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993. (Pubitemid 23346378)
19. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Lieberman, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994. (Pubitemid 24163411)
20. El-Deiry, W. S. Regulation of p53 downstream genes. Semin. Cancer Biol., 8: 345-357, 1998. (Pubitemid 29131356)
21. Fan, J., and Bertino, J. R. Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol. Pharmacol., 56: 966-972, 1999.
22. Smith, M. L. Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin. Breast Cancer Res. Treat., 58: 99-105, 1999. (Pubitemid 30032480)
23. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996. (Pubitemid 26055483)
24. Smith, M. L., Ford, J. M., Hollander, M. C., Bortnick, R. A., Amundson, S. A., Seo, Y. R., Deng, C-X., Hanawalt, P. C., and Fornace, A. J., Jr. p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd 45 genes. Mol. Cell. Biol., 20: 3705-3714, 2000. (Pubitemid 30243916)
25. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., Jr., and O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1997. (Pubitemid 27248224)
26. Smith, M. L., Kontny, H. U., Zhan, Q., Sreenath, A., O'Connor, P. M., and Fornace, A. J., Jr. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Oncogene, 13: 2255-2263, 1996. (Pubitemid 26411576)
27. Perez, R. P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer, 34: 1535-1542, 1998. (Pubitemid 28446333)
28. Dent, P., and Grant, S. Pharmacologic interruption of the mitogenactivated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin. Cancer Res., 7: 775-783, 2001. (Pubitemid 32708709)
29. Hayakawa, J., Ohmichi, M., Kurachi, H., Ikegami, H., Kimura, A., Matsuoka, T., Jikihara, H., Mercola, D., and Murata, Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem., 274: 31648-31654, 1999.
30. Persons, D. L., Yazlovitskaya, E. M., Cui, W., and Pelling, J. C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res., 5: 1007-1014, 1999. (Pubitemid 29233214)
31. Widmann, C., Gerwins, P., Johnson, N. L., Jarpe, M. B., and Johnson, G. L. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol. Cell. Biol., 18: 2416-2429, 1998. (Pubitemid 28152687)
32. Gebauer, G., Mirakhur, B., Nguyen, Q., Shore, S. K., Simpkins, H., and Dhanasekaran, N. Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma cells, 2008/C13. Int. J. Oncol., 16: 321-325, 2000.
33. Sanchez-Perez, I., and Perona, R. Lack of c-Jun activity increases survival to cisplatin. FEBS Lett., 453: 151-158, 1999. (Pubitemid 29335490)
34. Deak, J. C., Cross, J. V., Lewis, M., Qian, Y., Parrott, L. A., Distelhorst, C. W., and Templeton, D. J. Fas-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEKK1. Proc. Natl. Acad. Sci. USA, 95: 5595-5600, 1998. (Pubitemid 28224140)
35. Chang, M-J., Yu, W-D., Reyno, L. M., Modzelewski, R. A., Egorin, M. J., Erkmen, K., Vlock, D. R., Furmanski, P., and Johnson, C. S. Potentiation by interleukin 1α of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res., 54: 5380-5386, 1994.
36. 32P-postlabelling assay for the quantification of the major platinum-DNA adducts. Anal. Biochem., 275: 30-38, 1999.
37. Gaczynski, M., Briggs, J. A., Wedrychowski, A., Olinski, R., Uskokovic, M., Lian, J. B., Stein, G. S., and Briggs, R. C. cis-Diamminedichloroplatinum (II) cross-linking of the human myeloid cell nuclear antigen to DNA in HL-60 cells following 1,25-dihydroxy vitamin D3-induced monocyte differentiation. Cancer Res., 50: 1183-1188, 1990. (Pubitemid 20084008)
38. Eastman, A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum (II). Biochemistry, 22: 3927-3933, 1983. (Pubitemid 13035562)
39. 3) on the pharmacokinetics of paclitaxel or carboplatin: results of two Phase 1 studies. Proc. Am. Soc. Clin. Oncol., 19: 210a, 2000.
40. Widmann, C., Johnson, N. L., Gardner, A. M., Smith, R. J., and Johnson, G. L. Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene, 15: 2439-2447, 1997. (Pubitemid 27503530)
41. Mandic, A., Viktorsson, K., Molin, M., Akusjarvi, G., Eguchi, H., Hayashi, S-I., Toi, M., Hansson, J., Linder, S., and Shoshan, M. C. Cisplatin induces the proapoptotic conformation of Bak in a Δ-MEKK1-dependent manner. Mol. Cell. Biol., 21: 3684-3691, 2001. (Pubitemid 32466982)
42. Jurgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D., and Reed, J. C. Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl. Acad. Sci. USA, 95: 4997-5002, 1998. (Pubitemid 28208539)
43. Wood, D. E., Thomas, A., Devi, L. A., Berman, Y., Beavis, R. C., Reed, J. C., and Newcomb, E. W. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene, 17: 1069-1078, 1998. (Pubitemid 28444591)
44. Wood, D. E., and Newcomb, E. W. Cleavage of Bax enhances its cell death function. Exp. Cell Res., 256: 375-382, 2000. (Pubitemid 30244196)
45. Gao, G., and Dou, Q. P. N-terminal cleavage of Bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes Bcl-2- independent cytochrome c release and apoptotic cell death. J. Cell. Biochem., 80: 53-72, 2000.
46. Narvaez, C. J., and Welsh, J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J. Biol. Chem., 276: 9101-9107, 2001.
47. Persons, D. L., Yazlovitskaya, E. M., and Pelling, J. C. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J. Biol. Chem., 275: 35778-35785, 2000.
48. 3 analog EB1089 enhances the antiproliferative and apoptotic effects of Adriamycin in MCF-7 breast tumor cells. Breast Cancer Res. Treat., 63: 1-10, 2000.
49. 1-phase progression. Genes Dev., 13: 1501-1512, 1999.
50. Luo, Y., Hurwitz, J., and Massague, J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature (Lond.), 375: 159-161, 1995.
51. Rousseau, D., Cannella, D., Boulaire, J., Fitzgerald, P., Fotedar, A., and Fotedar, R. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Oncogene, 18: 4313-4325, 1999. (Pubitemid 29392372)
52. McDonald, E. R., III, Wu, G. S., Waldman, T., and El-Deiry, W. S. Repair defects in p21 Waf1/Cip1-/- human cancer cells. Cancer Res., 56: 2250-2255, 1996.
53. Waf1/Cip1-null human fibroblasts are deficient in nucleotide excision repair downstream the recruitment of PCNA to DNA repair sites. Oncogene, 20: 563-570, 2001.